The manufacture and distribution of falsified medicines has become an enormous, serious public health risk with an untold cost to lives.
On 9 February 2019, almost 7 years after its adoption, the final elements of the Falsified Medicines Directive (FMD) came into force introducing the end-to-end verification and safety features on prescription medicines across all Member States, representing a major advance to in patient safety due to the enhanced security of medicines in the supply chain.
The meeting titled “Improving patient safety with the FMD in the hospital pharmacy, status of implementation” was co-hosted by the EAASM and MEP José Inácio Faria (EPP, Portugal) on Tuesday 19th February 2019 in the EU Parliament. It brought together 52 participants, including hospital pharmacists, patient safety organisations, EU Commission officials, Health Attachés of the Council of the EU, European and national agencies, industries and academics to debate the challenges and potential practical solutions within the European hospital settings.
The roundtable aimed to create a positive and practical atmosphere and to help debate solutions that are supportive of the implementation of the verification of prescription packs in the hospital pharmacy setting. Keynote contributions came from MEP Faria, EAASM Executive Director Mike Isles, the European Medicines Verification Organisation, the Finnish Medicines Verification Organisation, DG Health and Food Safety of the European Commission, the European Association Hospital Pharmacists, and four national hospital representatives from Spain, France, Germany and the UK.
The EAASM intends to produce a report highlighting the key findings from a best practice point of view. Please find the event programme, the presentations, photographs and the videos of the whole event. These are the unedited version and there will be an edited version shortly.
If you would like further information, please do not hesitate to contact Laura Cigolot email@example.com